Results 181 to 190 of about 57,323 (255)

Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. [PDF]

Cancer Res
Woo SM, Kang JH, Choi W, Lee H, Jang H, Sim SH, Chun JW, Koh EB, Kim C, Ham W, Hong W, Kang M, Park J, Han S, Kim JW, Lee EW, Lee WJ, Kim SY.   +17 more
europepmc   +1 more source

Cathepsin V (CTSV) Shapes the Epigenetic–Immune Landscape of Bladder Cancer and Emerges as a Noninvasive Biomarker

International Journal of Urology, Volume 33, Issue 9, September 2026.
ABSTRACT Objective The aim of this study was to perform a comprehensive characterization of CTSV regulation in bladder cancer (BC) and its association with clinicopathological features, prognosis, and tumor stroma modulation using multi‐omics databases.
Wallax Augusto Silva Ferreira, Fabio Albuquerque Marchi, Glauco Akelinghton Freire Vitiello, Rolando André Rios Villacis, Ana Paula Drummond Rodrigues, Edivaldo Herculano Correa de Oliveira   +5 more
wiley   +1 more source

NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study. [PDF]

ESMO Gastrointest Oncol
Ueno M, Ikezawa K, Komatsu Y, Nagano H, Hisano T, Terashima T, Nio K, Morizane C, Shimizu S, Ozaka M, Ohyama H, Otsuru T, Sudo K, Mizuno N, Daniel C, Martín-Fernández L, Amellal N, Bernard K, Sasaki M.   +18 more
europepmc   +1 more source

Advances in therapeutic approaches to gastric cancer

CA: A Cancer Journal for Clinicians, Volume 76, Issue 5, September/October 2026.
Abstract Gastric cancer remains a leading cause of cancer‐related mortality worldwide, with nearly 1 million new cases diagnosed annually. Despite innovations in diagnosis, most patients still present at advanced stages, contributing to a poor prognosis.
Feng Wang, Zi‐Xian Wang, Yu‐Jing Zhang, Ye He, Jia‐Fu Ji, Yuan‐Fang Li, Xiu‐Juan Qu, Yi Ba, Shu‐Qiang Yuan, Rui‐Hua Xu   +9 more
wiley   +1 more source

Irinotecan Modulates Immune Checkpoints in Neuroblastoma. [PDF]

Immunotargets Ther
Lapidus T, Zorde-Khvalevsky E, Jolani A, Goldstein G, Peled A.   +4 more
europepmc   +1 more source

UGT1A1 and irinotecan: Ready for routine pharmacogenetic care. [PDF]

Br J Clin Pharmacol
Swen JJ.
europepmc   +1 more source

Irinotecan-Loaded Vaterite Microspheres for Drug Delivery: Drug Release and Dissolution Kinetics and Mechanism in an Aqueous Solution and Human Serum. [PDF]

Langmuir
Milner MP, Saint HA, Yang JM, Neumann CCM, Wansch K, Compton RG.   +5 more
europepmc   +1 more source

Tumour cell density quantified by artificial intelligence is associated with differential benefit from irinotecan-based chemo-radiotherapy in locally advanced rectal cancer: a post-hoc study of the phase 3 ARISTOTLE trial. [PDF]

EBioMedicine
Shen Z, Brand D, Simard M, West NP, Lopes A, Begum R, Zhang Y, Royle G, Sebag-Montefiore D, Collins Fekete CA, Hawkins MA.   +10 more
europepmc   +1 more source

A Phase II Clinical Trial of Chemotherapy Rechallenge with or without Targeted Therapy in Refractory Metastatic Colorectal Cancer. [PDF]

Oncol Res
Wang C, Huang M, Li W, Sheng X, Zhao X, Zhu X, Chen Z, Zhang Z, Li H, Guo W.   +9 more
europepmc   +1 more source

IGFBP-3 enhances irinotecan efficacy in colorectal cancer <i>via</i> ROS-mediated apoptosis and β-catenin suppression. [PDF]

Res Pharm Sci
Gharehkhani E, Karami M, Bagheri A, Kukandeh MR, Shokrzadeh M.   +4 more
europepmc   +1 more source